Search clinical trials for: cell cycle arrest

Total 57768 results

Fuzhou General Hospital

Not yet recruiting

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Non-small Cell Lung Cancer

China
CNAO National Center of Oncological Hadrontherapy

Recruiting

Carbon Ion Radiation Therapy in the Treatment of Mucous Melanomas of the Female Lower Genital Tract (CYCLE)

Gynecologic Cancer | Malignant Melanoma

Italy
National Institute of Allergy and Infectious Diseases...

Recruiting

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Chronic Granulomatous Disease

United States
North Eastern German Society of Gynaecological...
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Not yet recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
Children's Oncology Group

Recruiting

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Mixed Phenotype Acute Leukemia

United States, Australia, Canada
University of Washington

Recruiting

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma

United States
University of Washington
Incyte Corporation

Recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
National Cancer Institute (NCI)

Recruiting

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation | Peripheral Blood Stem Cell Transplantation

United States
Sumithira Vasu
National Cancer Institute (NCI)

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
Mayo Clinic

Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Italy, Canada, Israel, Korea, Republic of, Poland, Spain, Turkey
Jennifer Eva Selfridge

Recruiting

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Colorectal Cancer | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Plasma Cell Myeloma | Hematologic Malignancy | Rectum Cancer | Myeloproliferative Syndrome

United States
National Cancer Institute (NCI)

Recruiting

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Burkitt Lymphoma | Plasmablastic Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large Cell Lymphoma | B-Cell Neoplasm

United States
Vall d'Hebron Institute of Oncology
Hospital del Mar; Clinica Universidad de Navarra, Universidad de Navarra; Puerta... and other collaborators

Recruiting

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Breast Neoplasms

Spain
Kite, A Gilead Company

Recruiting

Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma (ZUMA-22)

Relapsed/Refractory Follicular Lymphoma

United States, Spain, United Kingdom, Italy, France, Japan, Germany
Chinese PLA General Hospital

Recruiting

Chidamide Bridging for CAR-T Therapy

Non Hodgkin's Lymphoma

China
TCRCure Biopharma Ltd.
Fudan University

Recruiting

HPV16 E6 TCR T Cells for Cervical Carcinoma

Cervical Carcinoma

China
Princess Maxima Center for Pediatric Oncology
University of Milano Bicocca; Amgen Europe B.V

Recruiting

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21)

Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

Norway, Finland, Denmark, Netherlands, Hungary, Argentina, Australia, Austria, Belgium, Czechia, France, Germany, Ireland, Italy, Japan, Portugal, Saudi Arabia, Sweden
National Cancer Institute (NCI)

Recruiting

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Embryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma

United States, Australia, Canada, New Zealand
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States, Puerto Rico
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

United States, France, Israel, Korea, Republic of, Spain, Taiwan, Netherlands, Czechia, Japan, Hungary, Germany, Denmark
Medical College of Wisconsin

Recruiting

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (LONCA)

B-cell Lymphoma | Burkitt Lymphoma

United States
Mayo Clinic

Recruiting

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors (PNeoVCA)

Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 and other conditions

United States
Stichting European Myeloma Network
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Multiple Myeloma

Netherlands, United States, Spain, Belgium, France, Italy, Germany, Japan, Canada, Australia, Sweden, Israel, United Kingdom, Czechia, Greece, Switzerland, Norway
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (AQUARIUS)

Amyloidosis

Canada, Italy, United States, Greece, China, Netherlands, Spain, France, Germany, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

Platinum-Resistant Ovarian Carcinoma

United States
University of Zurich

Recruiting

Visa-versa! Breaking Instead of Pushing the Pedals-C

Left Heart Failure

Switzerland
Fate Therapeutics

Recruiting

FT576 in Subjects With Multiple Myeloma

Multiple Myeloma | Myeloma

United States
The Foundation for Orthopaedics and Regenerative...

Recruiting

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Heart Disease

Congestive Heart Failure | Angina

Antigua and Barbuda, Argentina
Peking University

Not yet recruiting

Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors

Digestive System Tumors

China
Masonic Cancer Center, University of Minnesota

Not yet recruiting

Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL

Lymphoma Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Hematological Malignancy

United States
University of Ulm
Pfizer; AbbVie; Ludwig-Maximilians - University of Munich; Zentrum für Klinische... and other collaborators

Not yet recruiting

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia (VIWA-1)

Waldenstrom Macroglobulinemia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)

Oropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

China
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

B-Cell Lymphoma | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML)

United States
Sun Yat-sen University

Recruiting

Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma

Retinoblastoma

China
AIDS Malignancy Consortium
National Cancer Institute (NCI); Memorial Sloan Kettering Cancer Center

Not yet recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

HIV Infection | Recurrent Diffuse Large B-Cell Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent... and other conditions

United States
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Affiliated Hospital to Academy of Military Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking...

Recruiting

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Age Range ≥16 Years, Gender Unlimited | Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma | Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed | At Least One Positive Lesion According to the 2014... and other conditions

China
Shiraz University of Medical Sciences
National Institute of Medical Research Development (NIMAD), Iran; Cell Tech...

Recruiting

MSCs for Prevention of MI-induced HF (PREVENT-TAHA)

Heart Failure | STEMI | Myocardial Infarction, Acute | Cardiac Remodeling, Ventricular | Myocardial Infarction, Anterior Wall | Regenerative Medicine | Myocardial Infarction First

Iran, Islamic Republic of
National Cancer Institute (NCI)

Recruiting

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Kita-kyushu Lung Cancer Antigen 1, Human

United States
Haibo Zhang

Recruiting

Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC

Small Cell Lung Cancer (SCLC)

China
Marcela V. Maus, M.D.,Ph.D.

Recruiting

TriPRIL CAR T Cells in Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
National Cancer Institute (NCI)

Recruiting

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma | Hepatocellular Cancer | Metastatic Hepatocellular Carcinoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar Rhabdomyosarcoma

United States, Canada, Australia, Puerto Rico, Saudi Arabia
Kite, A Gilead Company

Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Relapsed and/or Refractory B-cell Lymphoma

United States, Netherlands, United Kingdom, Germany
Help Therapeutics
Xijing Hospital

Recruiting

Treating Congestive HF With hiPSC-CMs Through Endocardial Injection

Cardiovascular Diseases | Dilated Cardiomyopathy | Congestive Heart Failure

China
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States

Search clinical trials for: cell cycle arrest

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations